# Study Comparing Two Different Tablet Formulations Of Bosutinib

> **NCT00934674** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 30 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SKI-606 (Bosutinib)

## Key facts

- **NCT ID:** NCT00934674
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2009-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934674, "Study Comparing Two Different Tablet Formulations Of Bosutinib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00934674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*